DEXAMETHASONE
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
University of WashingtonSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cc-5013 David Bond, MD | Phase 2 | B |
Ifosfamide David Bond, MD | Phase 2 | CCC |
Tafasitamab David Bond, MD | Phase 2 | CCC |
Carboplatin David Bond, MD | Phase 2 | CCC |
Same molecule, other indications
DEXAMETHASONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →